中国癌症杂志 ›› 2019, Vol. 29 ›› Issue (11): 899-905.doi: 10.19401/j.cnki.1007-3639.2019.11.009

• 综述 • 上一篇    下一篇

CDK4/6抑制剂治疗三阴性乳腺癌的研究进展

朱秀之,陈 力,纪 磊,高 雨,王中华   

  1. 复旦大学附属肿瘤医院乳腺外科,上海市乳腺肿瘤重点实验室,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2019-11-30 发布日期:2019-12-11
  • 通信作者: 王中华 E-mail: zhonghuawang95@hotmail.com
  • 基金资助:
    北京乳腺病防治学会乳腺癌预防与诊治科研基金(2016);上海市抗癌协会青年医生“雏鹰”项目(2018)(SACA-CY1B02)。

Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors

ZHU Xiuzhi, CHEN Li, JI Lei, GAO Yu, WANG Zhonghua   

  1. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2019-11-30 Online:2019-12-11
  • Contact: WANG Zhonghua E-mail: zhonghuawang95@hotmail.com

摘要: 细胞周期的调控机制在肿瘤的发生、发展中发挥着重要作用。多项研究表明,在雌激素受体阳性、人类表皮生长因子受体阴性的乳腺癌患者中,细胞周期蛋白依赖性激酶4/6(cyclin-dependent kinase 4/6,CDK4/6)抑制剂具有较好的疗效,然而其在三阴性乳腺癌患者中的疗效仍需进一步探讨。Cyclin D-CDK4/6-INK4-Rb-E2F信号通路因具有调控细胞周期检查点的作用,被认为是乳腺癌潜在的治疗靶点。寻找三阴性乳腺癌与CDK4/6抑制剂关联的生物标志物,探究合理的药物配伍,筛选能从中获益的靶向人群,对临床工作具有重要意义。对CDK4/6抑制剂在三阴性乳腺癌的研究进展进行综述,探讨其应用前景及优化手段。

关键词: 细胞周期蛋白依赖激酶4/6, 细胞周期蛋白D和E, 三阴性乳腺癌, 视网膜母细胞瘤蛋白质, 雄激素受体

Abstract: The regulatory mechanism of cell cycle plays an important role in the occurrence and development of tumors. In recent years, a number of studies have shown that cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have good efficacy in patients with estrogen receptor-positive, human epidermal growth factor receptor-negative breast cancer, but their efficacy in patients with triple-negative breast cancer is still controversial. Cyclin D-CDK4/6 -INK4-Rb-E2F signaling pathway is considered as a potential therapeutic target for breast cancer due to its role in regulating cell cycle check points. It is of great significance to explore the molecular markers related to CDK4/6 inhibitors for triple-negative breast cancer, guide rational drug combination, and screen the population of triple-negative breast cancer patient who can benefit from this drug. In this article, we reviewed the research progress of CDK4/6 inhibitors in triple-negative breast cancer, and discussed their application prospects and optimization methods.

Key words: Cyclin-dependent kinase 4/6, Cyclin D/E, Triple-negative breast cancer, Retinoblastoma protein, Androgen receptor